|
 
We wanted to make you aware that FDA recently sent a warning letter to Stellalife, Inc. for marketing unapproved drugs in violation of the Federal Food, Drug, and Cosmetic Act. Some of their products have been the subject of microbial contamination concerns resulting in voluntary recalls by their contract manufacturer. Additionally, some of their products are for use in patients as young as 6 years old for open wounds and post-oral surgeries, which puts patients at risk.
Please feel free to share with your members.
About Us
The Public Engagement Staff resides within the Office of the Commissioner and falls under the Office of External Affairs. We aim to build stronger relationships with health professional organizations, patients and patient advocacy organizations, consumer groups, trade associations, think tanks and academia, and other interested parties, in order to better inform our policy making process, identify policy hurdles or misconceptions, and create strategic collaborations. For more information, please contact us at PublicEngagement@fda.hhs.gov. For patient specific inquiries, please contact us at Patients Ask FDA.
|
|
|
|
